CN119731193A - 环状肽衍生物及其制造方法和组合物 - Google Patents

环状肽衍生物及其制造方法和组合物 Download PDF

Info

Publication number
CN119731193A
CN119731193A CN202380057750.XA CN202380057750A CN119731193A CN 119731193 A CN119731193 A CN 119731193A CN 202380057750 A CN202380057750 A CN 202380057750A CN 119731193 A CN119731193 A CN 119731193A
Authority
CN
China
Prior art keywords
group
mmol
pharmaceutically acceptable
solvate
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380057750.XA
Other languages
English (en)
Chinese (zh)
Inventor
松本恒平
苅田祐马
安井航佑
田部七大
正司武嗣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DKS Co Ltd
Original Assignee
Dai Ichi Kogyo Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dai Ichi Kogyo Seiyaku Co Ltd filed Critical Dai Ichi Kogyo Seiyaku Co Ltd
Publication of CN119731193A publication Critical patent/CN119731193A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202380057750.XA 2022-08-04 2023-08-04 环状肽衍生物及其制造方法和组合物 Pending CN119731193A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2022-124810 2022-08-04
JP2022124810 2022-08-04
JP2022159060 2022-09-30
JP2022-159060 2022-09-30
PCT/JP2023/028632 WO2024029630A1 (ja) 2022-08-04 2023-08-04 環状ペプチド誘導体とその製造方法および組成物

Publications (1)

Publication Number Publication Date
CN119731193A true CN119731193A (zh) 2025-03-28

Family

ID=89849507

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380057750.XA Pending CN119731193A (zh) 2022-08-04 2023-08-04 环状肽衍生物及其制造方法和组合物

Country Status (12)

Country Link
US (1) US20260035407A1 (https=)
EP (1) EP4567042A1 (https=)
JP (1) JPWO2024029630A1 (https=)
KR (1) KR20250044905A (https=)
CN (1) CN119731193A (https=)
AU (1) AU2023317392A1 (https=)
CO (1) CO2025001948A2 (https=)
IL (1) IL318676A (https=)
MX (1) MX2025001373A (https=)
PE (1) PE20250797A1 (https=)
TW (1) TW202423948A (https=)
WO (1) WO2024029630A1 (https=)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
DE69839355T2 (de) 1997-07-29 2009-06-04 Alcon Laboratories, Inc., Fort Worth Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2016047638A1 (ja) * 2014-09-24 2016-03-31 国立大学法人岩手大学 環状ペプチド誘導体とその製造方法および組成物
JP7486328B2 (ja) * 2020-03-05 2024-05-17 株式会社バイオコクーン研究所 神経突起伸長促進剤、神経細胞の樹状突起発現促進剤、及び神経栄養因子様作用物質
JP7695662B2 (ja) * 2020-11-02 2025-06-19 公立大学法人大阪 環状ペプチド誘導体の製造方法及び環状ペプチド化合物の製造方法

Also Published As

Publication number Publication date
MX2025001373A (es) 2025-03-07
JPWO2024029630A1 (https=) 2024-02-08
IL318676A (en) 2025-03-01
KR20250044905A (ko) 2025-04-01
PE20250797A1 (es) 2025-03-14
AU2023317392A9 (en) 2026-02-12
US20260035407A1 (en) 2026-02-05
TW202423948A (zh) 2024-06-16
WO2024029630A1 (ja) 2024-02-08
CO2025001948A2 (es) 2025-03-06
EP4567042A1 (en) 2025-06-11
AU2023317392A1 (en) 2025-02-20

Similar Documents

Publication Publication Date Title
KR100635955B1 (ko) 아미노산 유도체 및 이들을 유효 성분으로서 함유하는 약제
JP2026016715A (ja) 狂犬病治療のための環状アミド化合物およびその方法
CN120152726A (zh) 用于处置或预防中枢神经系统损伤疾病的环状肽衍生物组合物
CN119731193A (zh) 环状肽衍生物及其制造方法和组合物
CN120187444A (zh) 用于处置或预防神经病理性疼痛和/或炎性疼痛的环状肽衍生物组合物
KR100633349B1 (ko) 아미노산 유도체 및 이들을 유효 성분으로서 함유하는 약제
CN119947740A (zh) 用于处置或预防眼科疾病的环状肽衍生物组合物
HK40122917A (zh) 环状肽衍生物及其制造方法和组合物
HK40128045A (zh) 用於处置或预防中枢神经系统损伤疾病的环状肽衍生物组合物
KR20020058077A (ko) 1,3,4-옥사디아졸린-2-온 유도체 및 그 유도체를 유효성분으로 하는 약제
JPH0699364B2 (ja) ズルシート類、その製造方法および該化合物の製造方法
WO2025169980A1 (ja) テストステロンの産生／分泌を調節するための環状ペプチド誘導体組成物
WO2025169981A1 (ja) 脳機能を改善するための環状ペプチド誘導体組成物
JP2023084946A (ja) 生理活性を有する新規化合物
HK40129190A (zh) 用於处置或预防神经病理性疼痛和/或炎性疼痛的环状肽衍生物组合物
JP2023084944A (ja) 生理活性を有する新規化合物
JP2022091476A (ja) 新規含窒素三環性骨格化合物およびその使用
KR20150075443A (ko) 신규 레바미피드 전구체의 염 및 이의 용도
CN108864083A (zh) 一类具有抗癌活性的氨基取代吲嗪类化合物及其衍生物
JPWO2001040263A1 (ja) １，３，４−オキサジアゾリン−２−オン誘導体およびその誘導体を有効成分とする薬剤
JPH07126279A (ja) アシルアミノ糖誘導体及びその製法
JPWO2000004005A1 (ja) アミノ酸誘導体およびそれらを有効成分として含有する薬剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40122917

Country of ref document: HK